Transgene presents its progress and financial situation as of Q3 2025

Transgene has shared promising new data regarding its TG4050 therapeutic vaccine, which focuses on preventing relapses of head and neck cancer. Presented at the SITC 2025 congress, this data reinforces the vaccine's potential as a monotherapy to generate effective immune responses.

The company also highlighted the progress of its myvac® platform for treating various types of operable solid tumors. In parallel, promising results from the BT-001 study, an oncolytic virus, were unveiled at ESMO 2025, demonstrating good antitumor activity in combination with anti-PD-1 therapy.

On the financial front, Transgene noted an increase in its Research Tax Credit, reaching €5.8 million in Q3 2025. With cash of €12.8 million as of September 30, 2025, the company remains funded until the end of 2026, thanks to significant support from its main shareholder.